Claire Marks

Claire Marks

Auto-generated profile, based on publicly available information

Claire Marks

Department of Statistics, University of Oxford, Oxford OX1 3LB, UK

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2016 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
JDJames Dunbar
James Dunbar
KKKonrad Krawczyk
Konrad Krawczyk
JLJinwoo Leem
Jinwoo Leem
CMClaire Marks
Claire Marks
JNJaroslaw Nowak
Jaroslaw Nowak
CDCharlotte M. Deane
Charlotte M. Deane
SAbPred is a server that makes predictions of the properties of antibodies focusing on their structures. Antibody informatics tools can help improve our understanding of immune responses to disease and aid in the design and engineering of therapeutic molecules. SAbPred is a single platform containing multiple applications which can: number and align sequences; automatically generate antibody variable fragment homology models; annotate such models with estimated accuracy alongside sequence and structural properties including potential developability issues; predict paratope residues; and predict epitope patches on protein antigens. The server is available at http://opig.stats.ox.ac.uk/webapps/sabpred.

26 September 2019 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
MRMatthew I J Raybould
Matthew I J Raybould
CMClaire Marks
Claire Marks
ALAlan P Lewis
Alan P Lewis
JSJiye Shi
Jiye Shi
ABAlexander Bujotzek
Alexander Bujotzek
CDCharlotte M Deane
Charlotte M Deane
The Therapeutic Structural Antibody Database (Thera-SAbDab; http://opig.stats.ox.ac.uk/webapps/therasabdab) tracks all antibody- and nanobody-related therapeutics recognized by the World Health Organisation (WHO), and identifies any corresponding structures in the Structural Antibody Database (SAbDab) with near-exact or exact variable domain sequence matches. Thera-SAbDab is synchronized with SAbDab to update weekly, reflecting new Protein Data Bank entries and the availability of new sequence data published by the WHO. Each therapeutic summary page lists structural coverage (with links to the appropriate SAbDab entries), alignments showing where any near-matches deviate in sequence, and accompanying metadata, such as intended target and investigated conditions. Thera-SAbDab can be queried by therapeutic name, by a combination of metadata, or by variable domain sequence - returning all therapeutics that are within a specified sequence identity over a specified region of the query. The sequences of all therapeutics listed in Thera-SAbDab (461 unique molecules, as of 5 August 2019) are downloadable as a single file with accompanying metadata.

10 June 2021 in Bioinformatics
Verified
Journal Article
Open access
PDF file
CMClaire Marks
Claire Marks
AHAlissa M Hummer
Alissa M Hummer
MCMark Chin
Mark Chin
CDCharlotte M Deane
Charlotte M Deane
Monoclonal antibody (mAb) therapeutics are often produced from non-human sources (typically murine), and can therefore generate immunogenic responses in humans. Humanization procedures aim to produce antibody therapeutics that do not elicit an immune response and are safe for human use, without impacting efficacy. Humanization is normally carried out in a largely trial-and-error experimental process. We have built machine learning classifiers that can discriminate between human and non-human antibody variable domain sequences using the large amount of repertoire data now available. Our classifiers consistently outperform the current best-in-class model for distinguishing human from murine sequences, and our output scores exhibit a negative relationship with the experimental immunogenicity of existing antibody therapeutics. We used our classifiers to develop a novel, computational humanization tool, Hu-mAb, that suggests mutations to an input sequence to reduce its immunogenicity. For a set of therapeutic antibodies with known precursor sequences, the mutations suggested by Hu-mAb show substantial overlap with those deduced experimentally. Hu-mAb is therefore an effective replacement for trial-and-error humanization experiments, producing similar results in a fraction of the time. Hu-mAb (humanness scoring and humanization) is freely available to use at opig.stats.ox.ac.uk/webapps/humab. Supplementary data are available at Bioinformatics online.

1 January 2017 in Computational and Structural Biotechnology Journal
Verified
Journal Article
Open access
CMC. Marks
C. Marks
CDC.M. Deane
C.M. Deane
Antibodies are proteins of the immune system that are able to bind to a huge variety of different substances, making them attractive candidates for therapeutic applications. Antibody structures have the potential to be useful during drug development, allowing the implementation of rational design procedures. The most challenging part of the antibody structure to experimentally determine or model is the H3 loop, which in addition is often the most important region in an antibody's binding site. This review summarises the approaches used so far in the pursuit of accurate computational H3 structure prediction.

13 December 2021 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
SRSarah A. Robinson
Sarah A. Robinson
MRMatthew I. J. Raybould
Matthew I. J. Raybould
CSConstantin Schneider
Constantin Schneider
WWWing Ki Wong
Wing Ki Wong
CMClaire Marks
Claire Marks
CDCharlotte M. Deane
Charlotte M. Deane
Identifying the epitope of an antibody is a key step in understanding its function and its potential as a therapeutic. Sequence-based clonal clustering can identify antibodies with similar epitope complementarity, however, antibodies from markedly different lineages but with similar structures can engage the same epitope. We describe a novel computational method for epitope profiling based on structural modelling and clustering. Using the method, we demonstrate that sequence dissimilar but functionally similar antibodies can be found across the Coronavirus Antibody Database, with high accuracy (92% of antibodies in multiple-occupancy structural clusters bind to consistent domains). Our approach functionally links antibodies with distinct genetic lineages, species origins, and coronavirus specificities. This indicates greater convergence exists in the immune responses to coronaviruses than is suggested by sequence-based approaches. Our results show that applying structural analytics to large class-specific antibody databases will enable high confidence structure-function relationships to be drawn, yielding new opportunities to identify functional convergence hitherto missed by sequence-only analysis.

16 January 2017 in Bioinformatics
Verified
Journal Article
Open access
PDF file
CMClaire Marks
Claire Marks
JNJaroslaw Nowak
Jaroslaw Nowak
SKStefan Klostermann
Stefan Klostermann
GGGuy Georges
Guy Georges
JDJames Dunbar
James Dunbar
CDCharlotte M Deane
Charlotte M Deane
Loops are often vital for protein function, however, their irregular structures make them difficult to model accurately. Current loop modelling algorithms can mostly be divided into two categories: knowledge-based, where databases of fragments are searched to find suitable conformations and ab initio, where conformations are generated computationally. Existing knowledge-based methods only use fragments that are the same length as the target, even though loops of slightly different lengths may adopt similar conformations. Here, we present a novel method, Sphinx, which combines ab initio techniques with the potential extra structural information contained within loops of a different length to improve structure prediction. We show that Sphinx is able to generate high-accuracy predictions and decoy sets enriched with near-native loop conformations, performing better than the ab initio algorithm on which it is based. In addition, it is able to provide predictions for every target, unlike some knowledge-based methods. Sphinx can be used successfully for the difficult problem of antibody H3 prediction, outperforming RosettaAntibody, one of the leading H3-specific ab initio methods, both in accuracy and speed. Sphinx is available at http://opig.stats.ox.ac.uk/webapps/sphinx. Supplementary data are available at Bioinformatics online.